Keywords
Last Name

Ritesh Rathore, MD

TitleAssociate Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHematology & Medical Oncology
Address25 Buick St
Boston MA 02215
Phone(401) 456-2077
Other Positions
InstitutionRoger Williams Medical Center

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS, Cohen SI. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. 2016 Oct; 76(14):1257-70. PMID: 27324746.
    View in: PubMed
  2. Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer. 2015; 2015:285193. PMID: 25802762.
    View in: PubMed
  3. Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res. 2015 May 15; 21(10):2305-14. PMID: 25688159.
    View in: PubMed
  4. Birnbaum A, Dipetrillo T, Rathore R, Merriam P, Wanebo H, Thomas A, Puthawala Y, Joyce D, Luppe D, Khurshid H, Follett N, Sio TT, Safran H. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study. Am J Clin Oncol. 2014 Apr; 37(2):162-6. PMID: 23275269.
    View in: PubMed
  5. Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, Colaiace WM, Rathore R. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study. Bone Marrow Transplant. 2014 Jan; 49(1):73-9. PMID: 24056738.
    View in: PubMed
  6. Ready NE, Rathore R, Johnson TT, Nadeem A, Chougule P, Ruhl C, Radie-Keane K, Theall K, Wanebo HJ, Marcello J, Kennedy T. Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2012 Feb; 35(1):6-12. PMID: 21293244.
    View in: PubMed
  7. Wanebo HJ, Rathore R, Chougule P, DiSiena MR, Koness RJ, McRae RG, Nigri PT, Radie-Keane K, Ready N. Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. Ann Surg Oncol. 2011 Nov; 18(12):3479-85. PMID: 21553142.
    View in: PubMed
  8. Birnbaum A, Dipetrillo T, Rathore R, Anderson E, Wanebo H, Puthwala Y, Joyce D, Safran H, Henderson D, Kennedy T, Ready N, Sio TT. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol. 2010 Apr; 33(2):144-7. PMID: 19786848.
    View in: PubMed
  9. Rathore R, Birnbaum A, Rathore B, DiPetrillo T, Kennedy T, Ready N. Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93). Cancer Chemother Pharmacol. 2010 Nov; 66(6):1013-7. PMID: 20130878.
    View in: PubMed
  10. Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, Iannitti D, Kennedy T. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol. 2010 Feb; 33(1):43-6. PMID: 19687731.
    View in: PubMed
  11. Chougule PB, Akhtar MS, Rathore R, Koness J, McRae R, Nigri P, Radie-Keane K, Kennedy T, Wanebo HJ, Ready N. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53). Head Neck. 2008 Mar; 30(3):289-96. PMID: 17657799.
    View in: PubMed
  12. Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006 Jan 1; 12(1):183-90. PMID: 16397041.
    View in: PubMed
  13. Tsai JY, Iannitti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K, Safran H. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. Am J Clin Oncol. 2005 Aug; 28(4):329-33. PMID: 16062072.
    View in: PubMed
  14. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY, Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004; 22(5):706-12. PMID: 15581051.
    View in: PubMed
  15. Safran H, DiPetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R, Wanebo H, Hughes M, Maia C, Tsai JY, Pasquariello T, Pepperell JR, Cioffi W, Kennedy T, Reeder L, Ng T, Adrian A, Goldstein L, Chak B, Choy H. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest. 2004; 22(5):670-7. PMID: 15581047.
    View in: PubMed
  16. Rathore R, Elfenbein GJ. The chronic leukemias: current and novel therapeutic approaches. Med Health R I. 2003 Aug; 86(8):240-2. PMID: 14582218.
    View in: PubMed
  17. Lum LG, Rathore R, Quesenberry PJ, Elfenbein GJ. Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells. Med Health R I. 2003 Aug; 86(8):247-8. PMID: 14582220.
    View in: PubMed
  18. Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ. Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells. Clin Breast Cancer. 2003 Aug; 4(3):212-7. PMID: 14499016.
    View in: PubMed
  19. Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T. A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer. 2002 Nov 1; 95(9):2000-5. PMID: 12404295.
    View in: PubMed
  20. Safran H, Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Crit Rev Oncol Hematol. 2002 Jul; 43(1):57-62. PMID: 12098607.
    View in: PubMed
  21. Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, Berzein K, Moore T, Iannitti D, Reiss P, Pasquariello T, Akerman P, Quirk D, Mass R, Goldstein L, Tantravahi U. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol. 2001 Oct; 24(5):496-9. PMID: 11586103.
    View in: PubMed
  22. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, Harrington D, Quirk D, Rathore R, Cruff D, Vakharia J, Vora S, Savarese D, Wanebo H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001 Apr 1; 49(5):1275-9. PMID: 11286834.
    View in: PubMed
  23. Butera J, Malachovsky M, Rathore R, Safran H. Novel approaches in development for the treatment of pancreatic cancer. Front Biosci. 1998 Nov 1; 3:E226-9. PMID: 9792896.
    View in: PubMed
  24. Fata F, Rathore R, Schiff C, Herzlich BC. Bronchiolitis obliterans organizing pneumonia as the first manifestation of polymyositis. South Med J. 1997 Feb; 90(2):227-30. PMID: 9042178.
    View in: PubMed
Ritesh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department